Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Anthracycline cardiotoxicity

CD8+ T cells as the missing link between doxorubicin cancer therapy and heart failure risk

Nature Cardiovascular Research volume 3, pages 890–892 (2024)Cite this article

Subjects

Doxorubicin treatment is a mainstay of cancer therapy but causes potent cardiotoxicity that exposes cancer survivors to the risk of heart failure. A study now identifies CD8+ T cells of the adaptive immune system as major culprits in the development of doxorubicin-induced cardiomyopathy and heart failure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cardiomyocyte cell death as a common denominator triggering autoimmunity in heart disease.

References

  1. van Dalen, E. C., Raphaël, M. F., Caron, H. N. & Kremer, L. C. M. Cochrane Database Syst. Rev. 9, CD006647 (2014).

    Google Scholar 

  2. Siebel, C. et al. BMC Pharmacol. Toxicol. 21, 37 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kong, C.-Y. et al. Int. J. Biol. Sci. 18, 760–770 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bayer, A. L. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-024-00507-y (2024).

    Article  Google Scholar 

  5. Lv, H. et al. J. Clin. Invest. 121, 1561–73 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sattler, S. ESC Heart Fail. 11, 611–614 (2024).

    Article  PubMed  Google Scholar 

  7. Forte, E. et al. Circulation 143, 821–836 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Fanti, S. et al. Circulation 146, 1930–1945 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Merten, M. Eur. Heart J. 42, ehab724.0798 (2021).

    Article  Google Scholar 

  10. Bermea, K. C. et al. Front. Immunol. 15, 1327372 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Martins, S. et al. BMC Cardiovasc. Disord. 23, 89 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sattler, S. Nat. Cardiovasc. Res. 3, 245–247 (2024).

    Article  Google Scholar 

  13. Locatelli, F. et al. N. Engl. J. Med. 382, 1811–1822 (2020).

    Article  PubMed  Google Scholar 

  14. Mallat, Z. & Binder, C. J. Nat. Cardiovasc. Res. 1, 431–444 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Moslehi, J. & Salem, J.-E. JACC CardioOncol. 4, 704–707 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Heart and Lung Institute, Imperial College London, Hammersmith Campus, London, UK

    Susanne Sattler & Senka Ljubojevic-Holzer

  2. Department of Pharmacology, Otto-Loewi Research Center, Medical University of Graz, Graz, Austria

    Susanne Sattler & Senka Ljubojevic-Holzer

  3. Department of Cardiology, LKH Univ. Klinikum Graz, Medical University of Graz, Graz, Austria

    Susanne Sattler & Senka Ljubojevic-Holzer

Authors
  1. Susanne Sattler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Senka Ljubojevic-Holzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Sattler.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sattler, S., Ljubojevic-Holzer, S. CD8+ T cells as the missing link between doxorubicin cancer therapy and heart failure risk. Nat Cardiovasc Res 3, 890–892 (2024). https://doi.org/10.1038/s44161-024-00513-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-024-00513-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing